Literature DB >> 15236191

Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice.

Peter Fickert1, Andrea Fuchsbichler, Martin Wagner, Gernot Zollner, Arthur Kaser, Herbert Tilg, Robert Krause, Frank Lammert, Cord Langner, Kurt Zatloukal, Hanns-Ulrich Marschall, Helmut Denk, Michael Trauner.   

Abstract

BACKGROUND & AIMS: Because the mechanisms leading to bile duct damage in sclerosing cholangitis are unknown, we aimed to determine the pathogenesis of bile duct injury in multidrug resistance gene (Mdr2) (Abcb4) knockout mice (Mdr2(-/-)) as a novel model of the disease.
METHODS: Mdr2(-/-) and wild-type controls (Mdr2(+/+)) were studied at 2, 4, and 8 weeks of age. Liver histology, ultrastructure, immunofluorescence microscopy (to study inflammatory cells, tight junction protein ZO-1, basement membrane protein laminin, fluorescence-labeled ursodeoxycholic acid), immunohistochemistry (for alpha-smooth muscle actin, nitrotyrosine), sirius red staining, bacterial cultures of intra-abdominal organs, and polymerase chain reaction (PCR) for Helicobacter bilis DNA were compared between both genotypes. Hepatic cytokine expression was determined by reverse-transcription PCR.
RESULTS: Bile ducts of Mdr2(-/-) showed disrupted tight junctions and basement membranes, bile acid leakage into portal tracts, induction of a portal inflammatory (CD11b, CD4-positive) infiltrate, and activation of proinflammatory (tumor necrosis factor [TNF]-alpha, interleukin [IL]-1beta) and profibrogenic cytokines (transforming growth factor [TGF]-beta1). This resulted in activation of periductal myofibroblasts, leading to periductal fibrosis, separating the peribiliary plexus from bile duct epithelial cells and, finally, causing atrophy and death of the bile duct epithelium. Bacterial translocation was not increased and H. bilis was not detectable in Mdr2(-/-).
CONCLUSIONS: Sclerosing cholangitis in Mdr2(-/-) mice is a multistep process with regurgitation of bile from leaky ducts into the portal tracts, leading to induction of periductal inflammation, followed by activation of periductal fibrogenesis, finally causing obliterative cholangitis owing to atrophy and death of bile duct epithelial cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15236191     DOI: 10.1053/j.gastro.2004.04.009

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  144 in total

1.  Mouse models of liver fibrosis mimic human liver fibrosis of different etiologies.

Authors:  Allyson K Martínez; Luca Maroni; Marco Marzioni; Syed T Ahmed; Mena Milad; Debolina Ray; Gianfranco Alpini; Shannon S Glaser
Journal:  Curr Pathobiol Rep       Date:  2014-12-01

2.  Prolonged darkness reduces liver fibrosis in a mouse model of primary sclerosing cholangitis by miR-200b down-regulation.

Authors:  Nan Wu; Fanyin Meng; Tianhao Zhou; Yuyan Han; Lindsey Kennedy; Julie Venter; Heather Francis; Sharon DeMorrow; Paolo Onori; Pietro Invernizzi; Francesca Bernuzzi; Romina Mancinelli; Eugenio Gaudio; Antonio Franchitto; Shannon Glaser; Gianfranco Alpini
Journal:  FASEB J       Date:  2017-06-20       Impact factor: 5.191

3.  Biliary phosphatidylcholine and lysophosphatidylcholine profiles in sclerosing cholangitis.

Authors:  Annika Gauss; Robert Ehehalt; Wolf-Dieter Lehmann; Gerhard Erben; Karl-Heinz Weiss; Yvonne Schaefer; Petra Kloeters-Plachky; Adolf Stiehl; Wolfgang Stremmel; Peter Sauer; Daniel Nils Gotthardt
Journal:  World J Gastroenterol       Date:  2013-09-07       Impact factor: 5.742

4.  Curcumin improves sclerosing cholangitis in Mdr2-/- mice by inhibition of cholangiocyte inflammatory response and portal myofibroblast proliferation.

Authors:  Anna Baghdasaryan; Thierry Claudel; Astrid Kosters; Judith Gumhold; Dagmar Silbert; Andrea Thüringer; Katharina Leski; Peter Fickert; Saul J Karpen; Michael Trauner
Journal:  Gut       Date:  2010-04       Impact factor: 23.059

Review 5.  Biliary wound healing, ductular reactions, and IL-6/gp130 signaling in the development of liver disease.

Authors:  A-J Demetris; John-G Lunz; Susan Specht; Isao Nozaki
Journal:  World J Gastroenterol       Date:  2006-06-14       Impact factor: 5.742

6.  Embryonic cholecystitis and defective gallbladder contraction in the Sox17-haploinsufficient mouse model of biliary atresia.

Authors:  Hiroki Higashiyama; Aisa Ozawa; Hiroyuki Sumitomo; Mami Uemura; Ko Fujino; Hitomi Igarashi; Kenya Imaimatsu; Naoki Tsunekawa; Yoshikazu Hirate; Masamichi Kurohmaru; Yukio Saijoh; Masami Kanai-Azuma; Yoshiakira Kanai
Journal:  Development       Date:  2017-04-21       Impact factor: 6.868

7.  Micro-computed tomography and nuclear magnetic resonance imaging for noninvasive, live-mouse cholangiography.

Authors:  James H Tabibian; Slobodan I Macura; Steven P O'Hara; Jeff L Fidler; James F Glockner; Naoki Takahashi; Val J Lowe; Bradley J Kemp; Prasanna K Mishra; Pamela S Tietz; Patrick L Splinter; Christy E Trussoni; Nicholas F LaRusso
Journal:  Lab Invest       Date:  2013-04-15       Impact factor: 5.662

Review 8.  The genetics of complex cholestatic disorders.

Authors:  Gideon M Hirschfield; Roger W Chapman; Tom H Karlsen; Frank Lammert; Konstantinos N Lazaridis; Andrew L Mason
Journal:  Gastroenterology       Date:  2013-04-10       Impact factor: 22.682

Review 9.  Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases.

Authors:  Michael Trauner; Peter Fickert; Emina Halilbasic; Tarek Moustafa
Journal:  Wien Med Wochenschr       Date:  2008

Review 10.  Primary sclerosing cholangitis: diagnosis, prognosis, and management.

Authors:  Siddharth Singh; Jayant A Talwalkar
Journal:  Clin Gastroenterol Hepatol       Date:  2013-02-27       Impact factor: 11.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.